Page 51 - Read Online

Page 10 of 10 Yapali et al. Hepatoma Res 2018;4:24 I http://dx.doi.org/10.20517/2394-5079.2018.57

55. El-Raziky, El-Hawary M, Esmat G, Abouzied AM, El-Koofy N, Mohsen N, Mansour S, Shaheen A, Abdel hamid M, El-Karaksy H.
Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J of Gastroenterol 2007;13:1828-32.
56. El-Nanawy AA, el Azzouni OF, Soliman AT, Amer AE, Demian RS, el-Sayed HM. Prevalence of hepatitis-C antibody seropositivity in
healthy Egyptian children and four high risk groups. J Trop Pediatrics 1995;41:341-3.
57. Jafri W, Jafri N, Yakoob J, islam M, Tirmizi SF, Jafar T, Akhtar S, Hamid S, Shah HA, Nizami SQ. Hepatitis B and C: prevalence and
risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis 2006;6:101.
58. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis 2006;10:272-7.
59. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat
M, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel
S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.
Liver Int 2011;31:61-80.
60. Bdour S. Hepatitis C virus infection in Jordanian hemodialysis units: serological diagnosis and genotyping. J Med Microbiol
2002;51:700-4.
61. Shemer-Avni Y, Astal Z, Kemper O, Najjar KJ, Yaari A, Hanuka N, Margalith M, Sikuler E. Hepatitis C virus infection and genotypes in
Southern Israel and the Gaza Strip. J Med Virol 1998;56:230-3.
62. Kabakçı Alagöz G, Karataylı SC, Karataylı E, Celik E, Keskin O, Dinç B, Cınar K, Idilman R, Yurdaydın C, Bozdayı AM. Hepatitis C
virus genotype distribution in Turkey remains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1, and
5’UTR regions in genotyping efficiency. Turk J Gastroenterol 2014;25:405-10.
63. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran is reflected by
phylogenetic analysis of NS5B region. J Med Virol 2004;74:246-52.
64. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35.
65. Chung RT, Baumert TF. Curing chronic hepatitis C-the arc of a medical triumph. N Engl J Med 2014;370:1576-8.
66. Edlin BR. Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infect Dis 2016;16:e196-201.
67. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;9:850-8.
68. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-
up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology
2012;55:1652-61.
69. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C
infection. Aliment Pharmacol Ther 2010;32:344-55.
70. Waked I, Doss W, El-Sayed M, Estes C, Razavi H, Shiha G, Yosry A, Esmat G. The current and future disease burden of chronic
hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014;15:45-52.
71. Estes C, Abdel-Kareem M, Abdel-Razek W,Abdel-Samea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic
burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther 2015;42:696-706.
72. Ziada DH, El Sadany S, Soliman H, Abd-Elsalam S, Salama M, Hawash N, Selim A, Hamisa M, Elsabagh HM. Prevalence of
hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: a single center study. J Egypt Natl Canc Inst 2016;28:257-62.
73. Stroffolini T, Sagnelli E, Rapicetta M, Felaco FM, Filippini P, Annella T, Petruzziello A, Chionne P, Sarrecchia B, Piccinino F. Hepatitis
B virus DNA in chronic HBsAg carriers: correlation with HBeAg/anti-HBe status, anti-HD and liver histology. Hepatogastroenterology
1992;39:62-5.
74. Sagnelli E, Felaco FM, Rapicetta M, Stroffolini T, Petruzziello A, Annella T, Chionne P, Pasquale G, Filippini P, Peinetti P. Interaction
between HDV and HBV infection in HBsAg-chronic carriers. Infection 1991;19:155-8.
75. Husa P, Linhartova A, Nemecek V, Husova L. Hepatitis D. Acta Virol 2005;49:219-25.
76. Değertekin H, Yalçin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an
analysis of clinical studies. Turk J Gastroenterol 2006;17:25-34.
77. Toukan AU, Abu-el-Rub OA, Abu-Laban SA, Tarawneh MS, Kamal MF, Hadler SC, Krawczynski K, Margolis HS, Maynard JE. The
epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan. Hepatology 1987;7:1340-5.
78. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, Krogsgaard K, Degos F, Carneiro
de Moura M. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The
EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
79. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection
on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut
2000;46:420-6.
80. Abbas Z, Abbas M, Abbas S, Shazi L. Hepatitis D and hepatocellular carcinoma. World J Hepatol 2015;7:777-86.
81. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011;(12):CD006002.
82. Chang MH. Hepatitis B virus and cancer prevention. Recent Results Cancer Res 2011;188:75-84.